DE69515702T2 - L-Tertiär-leucin-2-pyridylamid - Google Patents
L-Tertiär-leucin-2-pyridylamidInfo
- Publication number
- DE69515702T2 DE69515702T2 DE69515702T DE69515702T DE69515702T2 DE 69515702 T2 DE69515702 T2 DE 69515702T2 DE 69515702 T DE69515702 T DE 69515702T DE 69515702 T DE69515702 T DE 69515702T DE 69515702 T2 DE69515702 T2 DE 69515702T2
- Authority
- DE
- Germany
- Prior art keywords
- pyridylamide
- tertiary leucine
- leucine
- tertiary
- intermediat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9401034A GB9401034D0 (en) | 1994-01-20 | 1994-01-20 | Metalloproteinase inhibitors |
GB9415619A GB9415619D0 (en) | 1994-08-02 | 1994-08-02 | Metalloprotease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69515702D1 DE69515702D1 (de) | 2000-04-20 |
DE69515702T2 true DE69515702T2 (de) | 2000-08-10 |
Family
ID=26304192
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69515702T Expired - Fee Related DE69515702T2 (de) | 1994-01-20 | 1995-01-20 | L-Tertiär-leucin-2-pyridylamid |
DE69502378T Expired - Fee Related DE69502378T2 (de) | 1994-01-20 | 1995-01-20 | Metalloproteinaseinhibitoren |
DE19581347T Withdrawn DE19581347T1 (de) | 1994-01-20 | 1995-01-20 | Metalloproteinase-Inhibitoren |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69502378T Expired - Fee Related DE69502378T2 (de) | 1994-01-20 | 1995-01-20 | Metalloproteinaseinhibitoren |
DE19581347T Withdrawn DE19581347T1 (de) | 1994-01-20 | 1995-01-20 | Metalloproteinase-Inhibitoren |
Country Status (22)
Country | Link |
---|---|
US (2) | US5747514A (de) |
EP (2) | EP0822186B1 (de) |
JP (1) | JP3297053B2 (de) |
KR (1) | KR100418808B1 (de) |
CN (1) | CN1049651C (de) |
AT (2) | ATE165817T1 (de) |
AU (1) | AU682920B2 (de) |
BR (1) | BR9506535A (de) |
CZ (1) | CZ290145B6 (de) |
DE (3) | DE69515702T2 (de) |
DK (2) | DK0822186T3 (de) |
ES (2) | ES2144819T3 (de) |
FI (1) | FI962904A0 (de) |
GR (1) | GR3033209T3 (de) |
HU (1) | HUT75059A (de) |
NO (1) | NO306396B1 (de) |
NZ (1) | NZ278627A (de) |
PL (1) | PL179997B1 (de) |
PT (1) | PT822186E (de) |
SK (1) | SK281544B6 (de) |
UA (1) | UA43358C2 (de) |
WO (1) | WO1995019956A1 (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6037472A (en) | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
GB9601042D0 (en) * | 1996-01-17 | 1996-03-20 | Smithkline Beecham Plc | Medical use |
GB9414157D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Medical use |
GB9507799D0 (en) * | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
DE69632821T2 (de) * | 1995-04-25 | 2005-08-25 | Daiichi Fine Chemical Co., Ltd., Takaoka | In wasser hochlöslicher metalloproteinase-inhibitor |
US5677282A (en) * | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
ES2185750T3 (es) * | 1995-08-08 | 2003-05-01 | Ono Pharmaceutical Co | Derivados de acido hidroxamico utiles para la inhibicion gelatinasa. |
ES2184893T3 (es) | 1995-11-17 | 2003-04-16 | Warner Lambert Co | Inhibidores de sulfonamida de lasd metaloproteinasas matricales. |
US6127427A (en) * | 1995-11-23 | 2000-10-03 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
ES2202602T3 (es) * | 1996-04-23 | 2004-04-01 | PHARMACIA & UPJOHN COMPANY | Tiadiazolil(tio)ureas utiles como inhibidores de la metaloproteasa matriz. |
GB9609794D0 (en) * | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
AUPO048296A0 (en) * | 1996-06-14 | 1996-07-11 | Fujisawa Pharmaceutical Co., Ltd. | New compound and its preparation |
PT1021424E (pt) * | 1996-06-21 | 2003-06-30 | Upjohn Co | Amidas de tiadiazolo como inibidores da metaloproteinase de matriz |
US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
ES2181021T3 (es) | 1996-09-10 | 2003-02-16 | British Biotech Pharm | Derivados citostaticos del acido hidroxamico. |
CZ113999A3 (cs) * | 1996-10-02 | 1999-06-16 | Novartis Ag | Deriváty hydroxamové kyseliny, způsob jejich přípravy a jejich použití |
US6500983B2 (en) | 1996-10-02 | 2002-12-31 | Novartis Ag | Hydroxamic acid derivatives |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
ZA9818B (en) * | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
BR9807763A (pt) * | 1997-02-26 | 2000-02-22 | Glaxo Group Ltd | Composto, uso do mesmo, composição farmacêutica, e, processos para inibir a liberação intracelular do fator alfa da necrose tumoral, para inibir uma metaloprotease matriz, para inibição do escoamento de ectodomìnios de poteina da superfìcie da célula, para inibir o crescimento de metástases tumorais, ou um processo para o tratamento de diabete, ou um processo para o tratamento de artrite, em um sujeito mamìfero. |
US6197791B1 (en) | 1997-02-27 | 2001-03-06 | American Cyanamid Company | N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US5847148A (en) * | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
EP0897908A1 (de) * | 1997-08-19 | 1999-02-24 | Roche Diagnostics GmbH | 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
CN1125050C (zh) * | 1997-11-13 | 2003-10-22 | 英国生物技术药物有限公司 | 金属蛋白酶抑制剂 |
GB2333524A (en) * | 1997-11-13 | 1999-07-28 | British Biotech Pharm | Metalloproteinase inhibitors |
EA002971B1 (ru) | 1998-01-09 | 2002-12-26 | Пфайзер Инк. | Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
US6172064B1 (en) | 1998-08-26 | 2001-01-09 | Glaxo Wellcome Inc. | Formamides as therapeutic agents |
GB9818605D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therepeutic agents |
US6329400B1 (en) | 1998-08-26 | 2001-12-11 | Glaxo Wellcome Inc. | Formamide compounds as therapeutic agents |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
JP2003508028A (ja) * | 1999-07-28 | 2003-03-04 | ジェネンテック・インコーポレーテッド | 腫瘍治療のための組成物と方法 |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
EP1265865A2 (de) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Difluorbuttersäure-derivate und ihre verwendung als metalloprotease-hemmer |
AR030196A1 (es) * | 2000-03-21 | 2003-08-13 | Procter & Gamble | Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento |
IL151125A0 (en) | 2000-03-21 | 2003-04-10 | Procter & Gamble | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
US6803383B2 (en) * | 2000-03-27 | 2004-10-12 | The Scripps Research Institute | Inhibition of angiogenesis and tumor growth |
EP1282435A2 (de) | 2000-05-12 | 2003-02-12 | Immunex Corporation | Interleukin-1 inhibitoren zur behandlung von erkrankungen |
AR028606A1 (es) * | 2000-05-24 | 2003-05-14 | Smithkline Beecham Corp | Nuevos inhibidores de mmp-2/mmp-9 |
US6458552B1 (en) * | 2000-06-06 | 2002-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Metalloprotease peptide substrates and methods |
JP4825375B2 (ja) * | 2001-08-28 | 2011-11-30 | 株式会社 資生堂 | ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤 |
KR20050086949A (ko) * | 2002-12-27 | 2005-08-30 | 안지오테크 인터내셔날 아게 | 콜라졸리를 사용한 조성물 및 방법 |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
WO2005094879A2 (en) * | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human ox40l (cd 134l) |
EP1934331A4 (de) | 2005-10-14 | 2009-01-21 | Musc Found For Res Dev | Pax2 als ziel für die induktion von defb1-vermittelter tumorimmunität und krebstherapie |
CN101353320A (zh) * | 2007-07-24 | 2009-01-28 | 中国人民解放军军事医学科学院毒物药物研究所 | 基质金属蛋白酶抑制剂、含有它们的药物组合物及其制备方法和用途 |
US8709772B2 (en) | 2008-01-03 | 2014-04-29 | Verenium Corporation | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
GB0807139D0 (en) * | 2008-04-18 | 2008-05-21 | Syngenta Participations Ag | Novel microbiocides |
EP2307456B1 (de) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Die inhibierung von ang-2 zur behandlung multipler sklerose |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8827308D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
AU652596B2 (en) * | 1990-12-03 | 1994-09-01 | Celltech Limited | Peptidyl derivatives |
CA2058797A1 (en) * | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) * | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
CA2102890A1 (en) * | 1991-05-28 | 1992-11-29 | Soumya P. Sahoo | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents |
WO1992022523A2 (en) * | 1991-06-14 | 1992-12-23 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
KR100255203B1 (ko) * | 1991-11-08 | 2000-05-01 | 가와무라 요시부미 | 콜라게나제 저해제 |
AU3475393A (en) * | 1992-01-15 | 1993-08-03 | Merck & Co., Inc. | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents |
AU3899193A (en) * | 1992-04-07 | 1993-11-08 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
GB9211707D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
GB9211706D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
JPH08503475A (ja) * | 1992-11-25 | 1996-04-16 | メルク エンド カンパニー インコーポレーテッド | 抗変性活性剤としてのカルボキシ−ペプチジル誘導体 |
GB9307956D0 (en) * | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
-
1995
- 1995-01-20 DE DE69515702T patent/DE69515702T2/de not_active Expired - Fee Related
- 1995-01-20 EP EP97117543A patent/EP0822186B1/de not_active Expired - Lifetime
- 1995-01-20 AU AU14597/95A patent/AU682920B2/en not_active Ceased
- 1995-01-20 EP EP95906396A patent/EP0740652B1/de not_active Expired - Lifetime
- 1995-01-20 AT AT95906396T patent/ATE165817T1/de not_active IP Right Cessation
- 1995-01-20 JP JP51941795A patent/JP3297053B2/ja not_active Expired - Fee Related
- 1995-01-20 SK SK941-96A patent/SK281544B6/sk unknown
- 1995-01-20 ES ES97117543T patent/ES2144819T3/es not_active Expired - Lifetime
- 1995-01-20 WO PCT/GB1995/000111 patent/WO1995019956A1/en active IP Right Grant
- 1995-01-20 UA UA96083293A patent/UA43358C2/uk unknown
- 1995-01-20 PT PT97117543T patent/PT822186E/pt unknown
- 1995-01-20 ES ES95906396T patent/ES2117400T3/es not_active Expired - Lifetime
- 1995-01-20 KR KR1019960703916A patent/KR100418808B1/ko not_active IP Right Cessation
- 1995-01-20 NZ NZ278627A patent/NZ278627A/en unknown
- 1995-01-20 HU HU9601991A patent/HUT75059A/hu unknown
- 1995-01-20 AT AT97117543T patent/ATE190609T1/de not_active IP Right Cessation
- 1995-01-20 BR BR9506535A patent/BR9506535A/pt active Search and Examination
- 1995-01-20 DE DE69502378T patent/DE69502378T2/de not_active Expired - Fee Related
- 1995-01-20 DK DK97117543T patent/DK0822186T3/da active
- 1995-01-20 PL PL95315745A patent/PL179997B1/pl not_active IP Right Cessation
- 1995-01-20 DE DE19581347T patent/DE19581347T1/de not_active Withdrawn
- 1995-01-20 CZ CZ19962115A patent/CZ290145B6/cs not_active IP Right Cessation
- 1995-01-20 DK DK95906396T patent/DK0740652T3/da active
- 1995-01-20 CN CN95191248A patent/CN1049651C/zh not_active Expired - Fee Related
-
1996
- 1996-07-19 US US08/685,330 patent/US5747514A/en not_active Expired - Fee Related
- 1996-07-19 FI FI962904A patent/FI962904A0/fi not_active IP Right Cessation
- 1996-07-19 NO NO963030A patent/NO306396B1/no unknown
-
1998
- 1998-02-19 US US09/025,943 patent/US5859253A/en not_active Expired - Fee Related
-
2000
- 2000-04-12 GR GR20000400903T patent/GR3033209T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69515702D1 (de) | L-Tertiär-leucin-2-pyridylamid | |
ES2088839T1 (es) | Compuestos inhibidores de la proteasa retroviral. | |
GR3034197T3 (en) | Inhibitors of nitric oxide biosynthesis. | |
ATE197459T1 (de) | Thiazolobenzazepin-enthaltende inhibitoren mit zweifacher wirkung | |
MX9203032A (es) | Una solucion farmaceutica. | |
GB9715030D0 (en) | Metalloproteinase inhibitors | |
SE9100920D0 (sv) | New active compounds | |
GR3035239T3 (en) | 1,2-Diazepine containing dual action inhibitors | |
NO973578L (no) | Fremgangsmåte for fremstilling av mono-N-substituerte tetraazamakrosykliske forbindelser | |
FI930092A0 (fi) | Indanopyrrolidinkarbamater | |
SV1998000088A (es) | Compuestos farmaceuticos | |
ES2089176T3 (es) | Procedimiento para la preparacion de carboditioatos de piperidina fluorometil-sustituidos. | |
FI880868A (fi) | Välituotteina käyttökelpoisia tetratsoliyhdisteitä | |
RO91594A (ro) | Compozitie erbicida solida | |
ITBO920262A0 (it) | Dispositivi per realizzare fondi composti per scarpe | |
MY117874A (en) | Metalloproteinase inhibitors | |
ATE74348T1 (de) | Lipoxygenase-inhibitor verbindungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |